SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences,
will be presenting at the Credit Suisse 26th Annual Healthcare
Conference in Scottsdale, Arizona.
The live presentation takes place on Wednesday, November 8 at 9:30am ET (6:30am
PT). The presentation will be webcast and may be
accessed on the Company's website at
http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5
minutes prior to the presentation to download or install any
necessary software. A replay of the presentation will be
available on the website approximately one hour after the
conclusion of the event and will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a San Diego based
biotechnology company focused on neurologic, psychiatric and
endocrine related disorders. The Company markets
INGREZZA® (valbenazine) capsules in the United
States for the treatment of adults with tardive
dyskinesia. INGREZZA is a novel, selective vesicular monoamine
transporter 2 (VMAT2) inhibitor, and is the first FDA approved
product indicated for the treatment of adults with tardive
dyskinesia. The Company's three late-stage clinical programs
are: elagolix, a gonadotropin-releasing hormone antagonist for
women's health that is partnered with AbbVie Inc.; opicapone,
a novel, once-daily, peripherally-acting, highly-selective
catechol-o-methyltransferase inhibitor under investigation as
adjunct therapy to levodopa in Parkinson's patients; and INGREZZA,
a novel, once-daily, selective VMAT2 inhibitor under investigation
for the treatment of Tourette syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
View original
content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-credit-suisse-26th-annual-healthcare-conference-300546493.html
SOURCE Neurocrine Biosciences, Inc.